FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200574612> ?p ?o ?g. }

• W4200574612 endingPage "S112" @default.
• W4200574612 startingPage "S112" @default.
• W4200574612 abstract "Abstract Background In 2013, the Clinical and Laboratory Standards Institute recommended inducible clindamycin resistance (ICR) testing on macrolide-resistant Streptococcus pneumoniae isolates, which arises due to the ermB gene. Ribosomal methylation by ermB confers resistance to macrolides (high-level resistance), lincosamides and streptogramin B. The goal of our study is to characterize the prevalence of ICR among pediatric pneumococcal isolates. Methods We identified erythromycin-resistant(R) (minimum inhibitory concentration [MIC] ≥ 1 µg/mL) and clindamycin-susceptible(S) (MIC ≤ 0.25 µg/mL) pneumococcal isolates from pediatric patients seen at Children’s Mercy Hospital from 2007 to 2017. Determination of ICR was achieved via disk approximation (D-zone test) with standard erythromycin (15 µg) and clindamycin (2 µg) disks. Isolates with high-level erythromycin resistance (MIC ≥ 32µg/mL) were also tested for ermB gene by PCR. Positive and negative controls were used for D-zone test and ermB PCR. Results We identified 289 erythromycin-R pneumococcal isolates; of those 194 (67.1%) were clindamycin-S (Figure 1). One-hundred and sixty-nine isolates were available for ICR testing, 166 (98%) isolates represented non-invasive disease samples. Median age of patients with erythromycin-R and clindamycin-S isolates was 19 (range 0.1 – 180) months. None of the isolates expressed ICR based on the D-zone test. Thirteen of those isolates (7.7%) expressed high-level erythromycin-R (MIC range 32-128 µg/mL); all were negative for ermB. The most common serotypes/serogroups among erythromycin-R and clindamycin-S isolates were: 15 (n=22), 35B (n=19), 11 (n=16), 6 (n=16), 19A (n=14) and 33 (n=12). Conclusion Erythromycin-R and clindamycin-S pneumococcal isolates did not express ICR and isolates with high-level erythromycin-R did not carry ermB. Multicenter studies are needed to determine if ICR testing is required for macrolide-resistant pneumococcal isolates in the PCV13 era. Disclosures Liset Olarte, MD, MSc, GSK (Research Grant or Support)Merck (Research Grant or Support)Pfizer (Research Grant or Support)Sanofi (Research Grant or Support) Douglas S. Swanson, MD, Merck (Research Grant or Support)Pfizer (Research Grant or Support)Sanofi (Research Grant or Support)" @default.
• W4200574612 created "2021-12-31" @default.
• W4200574612 creator A5046228319 @default.
• W4200574612 creator A5053267770 @default.
• W4200574612 creator A5061183778 @default.
• W4200574612 creator A5090492397 @default.
• W4200574612 creator A5090832471 @default.
• W4200574612 date "2021-11-01" @default.
• W4200574612 modified "2023-09-27" @default.
• W4200574612 title "184. Inducible Clindamycin Resistance Testing on Pediatric Streptococcus pneumoniae Isolates" @default.
• W4200574612 doi "https://doi.org/10.1093/ofid/ofab466.184" @default.
• W4200574612 hasPublicationYear "2021" @default.
• W4200574612 type Work @default.
• W4200574612 citedByCount "0" @default.
• W4200574612 crossrefType "journal-article" @default.
• W4200574612 hasAuthorship W4200574612A5046228319 @default.
• W4200574612 hasAuthorship W4200574612A5053267770 @default.
• W4200574612 hasAuthorship W4200574612A5061183778 @default.
• W4200574612 hasAuthorship W4200574612A5090492397 @default.
• W4200574612 hasAuthorship W4200574612A5090832471 @default.
• W4200574612 hasBestOaLocation W42005746121 @default.
• W4200574612 hasConcept C2777458120 @default.
• W4200574612 hasConcept C2780206985 @default.
• W4200574612 hasConcept C2780685696 @default.
• W4200574612 hasConcept C2781253189 @default.
• W4200574612 hasConcept C501593827 @default.
• W4200574612 hasConcept C71924100 @default.
• W4200574612 hasConcept C86803240 @default.
• W4200574612 hasConcept C89423630 @default.
• W4200574612 hasConceptScore W4200574612C2777458120 @default.
• W4200574612 hasConceptScore W4200574612C2780206985 @default.
• W4200574612 hasConceptScore W4200574612C2780685696 @default.
• W4200574612 hasConceptScore W4200574612C2781253189 @default.
• W4200574612 hasConceptScore W4200574612C501593827 @default.
• W4200574612 hasConceptScore W4200574612C71924100 @default.
• W4200574612 hasConceptScore W4200574612C86803240 @default.
• W4200574612 hasConceptScore W4200574612C89423630 @default.
• W4200574612 hasIssue "Supplement_1" @default.
• W4200574612 hasLocation W42005746121 @default.
• W4200574612 hasLocation W42005746122 @default.
• W4200574612 hasOpenAccess W4200574612 @default.
• W4200574612 hasPrimaryLocation W42005746121 @default.
• W4200574612 hasRelatedWork W1982680999 @default.
• W4200574612 hasRelatedWork W2088001376 @default.
• W4200574612 hasRelatedWork W2126894939 @default.
• W4200574612 hasRelatedWork W2127686385 @default.
• W4200574612 hasRelatedWork W2150423207 @default.
• W4200574612 hasRelatedWork W2168122682 @default.
• W4200574612 hasRelatedWork W2183489708 @default.
• W4200574612 hasRelatedWork W2376250663 @default.
• W4200574612 hasRelatedWork W2380088530 @default.
• W4200574612 hasRelatedWork W2531239281 @default.
• W4200574612 hasVolume "8" @default.
• W4200574612 isParatext "false" @default.
• W4200574612 isRetracted "false" @default.
• W4200574612 workType "article" @default.